臨床試験

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT: NCT05977036 · RECRUITING

NCT識別子NCT05977036

ステータスRECRUITING

開始日2024-09-25

完了2035-09-30

SponsorWashington University School of Medicine (OTHER)

First posted2023-08-04

Last updated2026-10-09

概要

This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with hormone receptor (HR) positive, HER-2 negative metastatic or unresectable breast cancer receiving first-line or second-line treatment.

公式ソース

ClinicalTrials.govで見る →

データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。